Patient characteristics of the intention-to-treat cohorts
| . | Clinical cohort . | Molecular cohort . | ||||
|---|---|---|---|---|---|---|
| . | No HDT/ASCT . | HDT/ASCT . | P . | No HDT/ASCT . | HDT/ASCT . | P . |
| No. of patients | 215 | 216 | 69 | 88 | ||
| ASCT received at frontline, n/N (%) | 4/215 (2) | 156/216 (72) | <.001 | 2/69 (3) | 69/88 (78) | <.001 |
| ASCT received at any timepoint, n/N (%) | 28/193 (15) | 173/205 (84) | <.001 | 11/68 (16) | 78/85 (92) | <.001 |
| Age, median (range), y | 50 (25-60) | 51 (19-60) | .93 | 50 (29-60) | 51 (19-60) | .39 |
| Male sex, n/N (%) | 116/215 (54) | 105/216 (49) | .29 | 44/69 (64) | 44/88 (50) | .11 |
| Stage III/IV, n/N (%) | 212/215 (99) | 214/216 (99) | .69 | 69/69 (100) | 87/88 (99) | >.99 |
| FLIPI high risk, n/N (%) | 54/203 (27) | 55/197 (28) | .82 | 20/69 (29) | 22/87 (25) | .72 |
| m7-FLIPI high risk, n/N (%) | NA | NA | NA | 16/69 (23) | 12/88 (14) | .14 |
| POD24-PI high risk, n/N (%) | NA | NA | NA | 17/69 (25) | 18/88 (20) | .57 |
| ECOG PS >1, n/N (%) | 12/210 (6) | 9/210 (4) | .66 | 4/69 (6) | 5/87 (6) | >.99 |
| Grade 3 FL, n/N (%) | 2/181 (1) | 5/181 (3) | .45 | 0/63 (0) | 3/81 (4) | .26 |
| EZH2 mutated, n/N (%) | NA | NA | NA | 12/69 (17) | 21/88 (24) | .43 |
| TP53 mutated, n/N (%) | NA | NA | NA | 2/69 (3) | 2/88 (2) | >.99 |
| CR rate, n/N (%) | 42/214 (20) | 47/213 (22) | .55 | 10/69 (14) | 18/88 (20) | .40 |
| POD24, n/N (%) | 32/202 (16) | 24/194 (12) | .39 | 9/66 (14) | 6/81 (7) | .28 |
| . | Clinical cohort . | Molecular cohort . | ||||
|---|---|---|---|---|---|---|
| . | No HDT/ASCT . | HDT/ASCT . | P . | No HDT/ASCT . | HDT/ASCT . | P . |
| No. of patients | 215 | 216 | 69 | 88 | ||
| ASCT received at frontline, n/N (%) | 4/215 (2) | 156/216 (72) | <.001 | 2/69 (3) | 69/88 (78) | <.001 |
| ASCT received at any timepoint, n/N (%) | 28/193 (15) | 173/205 (84) | <.001 | 11/68 (16) | 78/85 (92) | <.001 |
| Age, median (range), y | 50 (25-60) | 51 (19-60) | .93 | 50 (29-60) | 51 (19-60) | .39 |
| Male sex, n/N (%) | 116/215 (54) | 105/216 (49) | .29 | 44/69 (64) | 44/88 (50) | .11 |
| Stage III/IV, n/N (%) | 212/215 (99) | 214/216 (99) | .69 | 69/69 (100) | 87/88 (99) | >.99 |
| FLIPI high risk, n/N (%) | 54/203 (27) | 55/197 (28) | .82 | 20/69 (29) | 22/87 (25) | .72 |
| m7-FLIPI high risk, n/N (%) | NA | NA | NA | 16/69 (23) | 12/88 (14) | .14 |
| POD24-PI high risk, n/N (%) | NA | NA | NA | 17/69 (25) | 18/88 (20) | .57 |
| ECOG PS >1, n/N (%) | 12/210 (6) | 9/210 (4) | .66 | 4/69 (6) | 5/87 (6) | >.99 |
| Grade 3 FL, n/N (%) | 2/181 (1) | 5/181 (3) | .45 | 0/63 (0) | 3/81 (4) | .26 |
| EZH2 mutated, n/N (%) | NA | NA | NA | 12/69 (17) | 21/88 (24) | .43 |
| TP53 mutated, n/N (%) | NA | NA | NA | 2/69 (3) | 2/88 (2) | >.99 |
| CR rate, n/N (%) | 42/214 (20) | 47/213 (22) | .55 | 10/69 (14) | 18/88 (20) | .40 |
| POD24, n/N (%) | 32/202 (16) | 24/194 (12) | .39 | 9/66 (14) | 6/81 (7) | .28 |
P values were derived from Fisher’s exact test (categorial) or Wilcoxon test (continuous), respectively.
NA, not available.